BPDCN treatment algorithm. Aggressive therapy, including allogeneic SCT, should be considered for all patients who have the performance status and comorbidity scores to support this rigorous process. Early referral for clinical trial is warranted and encouraged. We prefer to lead with an AML regimen; given the high rate of CNS relapse, intrathecal therapy (IT) is strongly recommended. CCI, Charlson Comorbidity Index; MTX, methotrexate.